Management
Moncef Jendoubi, PhD, DES – President and Chief Executive Officer
Dr. Jendoubi is the founder of Milagen, Inc. Since March 1997, Dr. Jendoubi has served as President and CEO leading the company maturation process. Through his leadership and vision, Milagen, Inc. has developed from an R&D discovery and validation biotechnology with a focus on tissue and serum cancer biomarkers, to an immunodiagnostic company dedicated to the development, manufacturing and commercialization of innovative products for the early detection of major diseases with unmet needs.
Dr. Jendoubi was educated in France, and holds several degrees, including a M.S. in Genetics, in Biochemistry, a Ph.D. in Molecular Biology and a "Doctorat D'Etat es Sciences" in Immunology. He trained at the Pasteur Institute where he held the position of Associate Professor in the Department of Immunology.
In 1987 Dr. Jendoubi joined the National Institutes of Health (NIH), first as Visiting Scientist at the NIAID, then, in 1990, he became a Chief of the Genetics and Molecular Immunology Section of the Laboratory of Immunology at the NEI.
Dr. Jendoubi is an internationally recognized and highly respected scientist, and the author of over 60 publications, and several patents. He is a member of several academic societies, including the American Association of Clinical Oncology (ASCO), and the American Association for Clinical Chemistry (AACC).
Rosaura P.C. Valle, PhD – VP of Operations & Strategic Alliances
Dr. Valle is part of Milagen executive team. She joined the Company since inception, and held several key positions contributing to the establishment of Milagen as a research and development biotechnology company. Dr. Valle was instrumental in establishing a number of collaborations with academic and clinical centers in the US as well as abroad.
As VP of Operations & Strategic Alliances since 2001, Dr. Valle oversees all operations, human resources, and intellectual property at Milagen. In addition, she is in charge of all academic collaborations, business relations, and government contracting. Dr. Valle has acquired extensive experience with government agencies, as she trained at the NIDDK of the National Institutes of Health (NIH) in Bethesda from 1989 to 1994, and also spent three years at the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) prior to joining Milagen.
Dr. Valle received her PhD from the University Denis Diderot in Paris, France, in 1989, and is the author of a number of scientific publications in molecular virology, as well as in the applications of Milagen technologies in biomarker development and early diagnostics.
Christine Chavany, PhD – Regulatory Affairs Director
Dr. Chavany has led Milagen research and development effort in biomarker discovery and development in cancer and other major human diseases since inception of the company in 1997. She has been instrumental in the development of Milagen technologies, and has been Principal Investigator in a number of government funded projects.
Dr. Chavany has recently joined Milagen Management Team as the Acting Director of Regulatory Affairs to oversee the clinical development of Milagen immunodiagnostic assay product pipeline, and to provide guidance in regulatory affairs and compliance, being the liaison with the FDA and other government agencies. Dr. Chavany is leading Milagen effort to set up a reference laboratory with an emphasis on the early detection of major cancers.
Dr. Chavany received her PhD in Pharmacology from the University of Orsay in 1991, and trained at the National Cancer Institute from 1991 to 1995 focusing on the anti-cancer activity of RNAi. She also held positions at the National Institutes of Health (NIH) and in the biotech sector, working on transgenic mice and gene therapy, prior to joining Milagen.
Dr. Chavany is a long-lasting member of the American Cancer Society, and is Regulatory Affair Certified by the Regulatory Affair Professional Society since 2001.